Lazard Asset Management
DNA icon

Lazard Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Lazard Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-427
Closed -$4K – 2362
2024
Q4 		$4K Buy
+427
New +$3.66K ﹤0.01% 2138
2023
Q1 		– Sell
-760
Closed -$51K – 2353
2022
Q4 		$51K Buy
+760
New +$69.9K ﹤0.01% 1799
2022
Q1 		– Sell
-71
Closed -$23K – 2371
2021
Q4 		$23K Buy
+71
New +$33.7K ﹤0.01% 2021

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Lazard Asset Management's DNA Position: Q1 2025 in Review

Lazard Asset Management sold out of Ginkgo Bioworks (DNA) in Q1 2025, closing a stake of 427 shares — an estimated $4K sold.

Lazard Asset Management first reported a position in DNA in Q4 2021 and held it in 3 quarters. The position peaked at $51K in Q4 2022. 167 funds tracked by Wall St. Rank hold DNA as of Q1 2025.

  • Lazard Asset Management reported no remaining Ginkgo Bioworks position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 427 Ginkgo Bioworks shares in Q1 2025, an estimated $4K.
  • Lazard Asset Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 3 quarters.
  • Lazard Asset Management's Ginkgo Bioworks position peaked at $51K in Q4 2022.
  • 167 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.